[Ad hoc announcement pursuant to Art. 53 LR] Roche exceeds guidance
and achieves sales growth of 1% (CER) for 2023 despite sharp
COVID-19 sales decline
- Group sales grow
by 1%1 at constant exchange rates (CER; -7% in CHF),
more than offsetting the decline in COVID-19-related sales and
biosimilar erosion, and thereby exceeding 2023 guidance
- Excluding COVID-19 products,
Group sales increase by 8%
- Pharmaceuticals
Division sales increase by 6% (excluding
COVID-19 medicine Ronapreve: +9%) due to ongoing high demand for
newer medicines, with eye medicine Vabysmo continuing to be the top
growth driver, followed by Ocrevus (multiple sclerosis), Hemlibra
(haemophilia A) and Polivy (blood cancer)
- Diagnostics Division
sales are 13% lower due to high demand for COVID-19 tests
in 2022; strong momentum in the Diagnostics Division’s base
business continues with an increase of 7%
- Highlights in the
fourth quarter of 2023 and January 2024:
- US approval of
Vabysmo (retinal vein occlusion, a severe eye
disease)
- US priority review of
Xolair (food allergies)
- EU approval of subcutaneous form of
Tecentriq (cancer immunotherapy)
- Positive phase III data for
inavolisib (breast cancer),
Xolair (food allergies) and
Hemlibra (babies with severe haemophilia A);
positive longer-term data for Columvi and
Lunsumio (blood cancer); positive long-term data
for Kadcyla (breast cancer)
- US Breakthrough Device Designation
for Elecsys NfL test (multiple sclerosis); launch
of innovative new assays (hepatitis B and E)
- Acquisitions of
Telavant (inflammatory bowel disease and other
immunologic disorders) and Carmot (obesity and
other metabolic diseases);
acquisition agreement with LumiraDx (point-of-care
technology platform)
- Roche (3rd) and Chugai (2nd) in
Dow Jones Sustainability Indices
- IFRS net income
increases 7% (-9% in CHF) to CHF 12.4 billion
- Core earnings per
share increase by 6% (-9% in CHF)
- Board proposes
dividend increase to CHF 9.60
- Change in Board of
Directors
Outlook for 2024
Roche expects an increase in Group sales in the
mid single digit range (at constant exchange rates). Core
earnings per share are targeted to develop broadly in line
with sales growth (at constant exchange rates), excluding the
impact from resolution of tax disputes in 2023. Roche expects to
further increase its dividend in Swiss francs.
Key figures |
CHF millions |
% change |
January–December 2023 |
2023 |
2022 |
At CER1 |
In CHF |
Group sales |
58,716 |
63,281 |
1 |
-7 |
Pharmaceuticals Division |
44,612 |
45,551 |
6 |
-2 |
Diagnostics Division |
14,104 |
17,730 |
-13 |
-20 |
Core operating profit |
19,240 |
22,173 |
-1 |
-13 |
Core EPS – diluted (CHF) |
18.57 |
20.30 |
6 |
-9 |
IFRS net income |
12,358 |
13,531 |
7 |
-9 |
Roche CEO Thomas Schinecker: “We achieved good sales growth that
more than offset the sharp drop in COVID-19 sales. Roche’s base
business – excluding COVID-19 – continued its strong growth
momentum with +8% at constant exchange rates. As a result, we
exceeded our guidance for 2023. At the same time, the significant
appreciation of the Swiss franc versus most currencies strongly
impacted results when reported in Swiss francs. We also made good
progress in both our pharma and diagnostics product pipeline. One
recent highlight is inavolisib, an oral therapy investigated in
phase III trials which showed a reduction of more than 50% in the
risk of death or worsening disease for patients suffering from
advanced, hard-to-treat breast cancer. We look forward to bringing
this medicine to patients as soon as possible. Our new partnerships
and acquisitions address disease areas with high unmet needs, such
as inflammatory bowel disease and cardiometabolic disease. We are
well positioned for future growth.”
Change in Board of Directors
Bernard Poussot (born 1952), who has been a member of the Board of
Directors since 2015, has decided not to stand for re-election at
the Annual General Meeting in 2024. All other members of the Board
will be proposed for re-election.
Severin Schwan, Chairman of the Board: “Bernard Poussot’s
extensive leadership experience and profound knowledge of the
pharmaceutical industry have resulted in significant contributions
to Roche. I am sincerely thankful to him.”
Group results
In 2023, Roche achieved sales growth of 1% (-7% in
CHF) to CHF 58.7 billion, exceeding the company’s guidance for the
year. This increase more than made up for the expected decline in
COVID-19-related sales, amounting to CHF 4.3 billion, and the
effects of biosimilar erosion on our cancer medicines
MabThera/Rituxan, Herceptin and Avastin, which totalled CHF 1.1
billion – resulting in an overall impact of CHF 5.4 billion (at
CER).
The Swiss franc significantly appreciated versus most
currencies, impacting results when reported in Swiss francs
compared to constant exchange rates.
Core operating profit was down 1% (-13% in CHF)
to CHF 19.2 billion. The good sales performance and a return
towards a pre-COVID-19 sales mix resulted in an improved gross
margin. This was offset by continued investments in pharmaceutical
research, development and launches of new products. Additionally,
the patent settlement income in Japan in 2022 affected the growth
rate in 2023.
IFRS net income increased by 7% (-9% in CHF) to
CHF 12.4 billion due to the increase in operating profit (IFRS) and
lower income tax expenses.
Core earnings per share rose by 6% (-9% in
CHF), including the positive impact from the resolution of tax
disputes in 2023.
Sales in the Pharmaceuticals Division increased
by 6% to CHF 44.6 billion, with newer medicines for severe diseases
continuing their strong growth.
The top five growth drivers – Vabysmo (severe eye diseases),
Ocrevus (multiple sclerosis), Hemlibra (haemophilia A), Polivy
(blood cancer) and Phesgo (breast cancer) – achieved total sales of
CHF 14.8 billion. This represents a plus of CHF 4.3 billion at CER
compared to 2022.
Vabysmo, launched only in early 2022, reached sales of CHF 2.4
billion, and has become one of the best-selling medicines of
Roche.
In the United States, sales rose by 8%.
Vabysmo, Ocrevus and Hemlibra were the main growth drivers. This
increase was partly offset by declining sales of medicines with
expired patents.
Sales in Europe grew by 6%, with key
contributions from Germany, France and the UK. The sales growth of
Vabysmo, Phesgo, Evrysdi (spinal muscular atrophy), Hemlibra and
Ocrevus more than compensated for the lower sales of Ronapreve
(COVID-19) and medicines with expired patents.
In Japan, sales were down by 14%, mainly due to
lower supply of Ronapreve to the government. Excluding Ronapreve,
sales in Japan grew by 6%. This increase was fueled by the strong
performance of newer medicines such as Polivy and Vabysmo, which
effectively compensated for the impact of biosimilars.
Sales in the International region grew by 13%,
led by China, Brazil and Canada. In China, sales rose by 6%, with
Tamiflu (influenza), Xofluza (influenza) and the cancer medicines
Polivy, Tecentriq and Perjeta being the key growth drivers, more
than offsetting the impact of biosimilars and lower sales of
CellCept (transplantation).
The Diagnostics Division’s base
business sales increased by 7%, with immunodiagnostic
products, particularly cardiac tests, and diagnostics solutions for
clinical chemistry and for advanced staining contributing
significantly to this growth.
Overall, the Diagnostics Division reported
sales of CHF 14.1 billion, a decline of 13%. This reflects the
anticipated significant drop in demand for COVID-19-related
products (sales of CHF 0.8 billion in 2023, compared to sales of
CHF 4.1 billion in 2022, both at CER).
With lower demand for COVID-19 testing, sales in the
North America, EMEA and
Asia-Pacific regions decreased by 21%, 13% and
11%, respectively. The division's base business grew across all
regions.
Pharmaceuticals Division: pipeline
With 82 new molecular entities (NMEs) and a total of 146 projects,
Roche has a promising pipeline with a wide variety of therapeutic
approaches.
Pharmaceuticals research and development (R&D) expenditure
grew by 6% to CHF 11.5 billion (Group R&D: +5% to CHF 13.2
billion). Oncology remained the primary area for R&D and cancer
immunotherapy a key driver. Additionally, substantial investments
were also made in neuroscience, ophthalmology and immunology.
Pharmaceuticals: key milestones in the fourth quarter of
2023
(incl. January 2024*)
Compound |
Milestone |
Regulatory |
Tecentriq SC*
Subcutaneous cancer immunotherapy |
EU approves Tecentriq SC, the EU’s first subcutaneous
anti-PD-(L)1 cancer immunotherapy injection for multiple cancer
types
- Subcutaneous (SC) injection offers the potential for a faster,
more convenient alternative to intravenous (IV) infusion and is
preferred by cancer patients, nurses and physicians
- Tecentriq SC reduces the time required to administer the
treatment by approximately 80%, compared with standard IV
infusion
- Roche is working closely with national health systems in Europe
to ensure patients can access Tecentriq SC as quickly as
possible
More information: Media Release, 16 January 2024 |
Xolair
Food allergies
|
Based on positive National Institutes of Health phase III
study results, FDA grants priority review to Xolair for children
and adults with food allergies
- If approved, Xolair would be the first medicine to reduce
allergic reactions to multiple foods following accidental
exposure
- Interim analysis results from first-of-its-kind phase III
OUtMATCH study showed that Xolair significantly increased the
amount of peanut, milk, egg and cashew which it took to cause an
allergic reaction
- In the United States 17 million people have confirmed food
allergies, and more than 40% of children and over 50% of adults
with food allergies have experienced a severe reaction at least
once in their lifetime
More information: Media Release, 19 December 2023 |
Vabysmo
Severe eye diseases |
FDA approves Vabysmo for the treatment of retinal vein
occlusion (RVO)
- RVO is the third indication for Vabysmo, in addition to
neovascular or ‘wet’ age-related macular degeneration and diabetic
macular oedema
- Approval is based on two phase III studies demonstrating early
and sustained vision improvements that were non-inferior to
aflibercept
- Vabysmo also demonstrated rapid and robust drying of retinal
fluid
More information: Media Release, 27 October 2023 |
Phase III, pivotal and other key readouts; data
presentations; acquisitions and partnerships |
Columvi
Blood cancer
Lunsumio
Blood cancer
|
New data for Columvi and Lunsumio presented at the annual
meeting of the American Society of Hematology (ASH) 2023 support
continued benefit for people with lymphoma
- Longer-term data from pivotal studies of fixed-duration Columvi
and Lunsumio continue to show durable responses in people with
heavily pre-treated lymphomas
- New data reinforce the potential of combination regimens in
earlier treatment settings and add to the robust body of evidence
supporting ongoing phase III studies
More information: Media Release, 11 December 2023 |
Hemlibra
Haemophilia A
|
New data reinforce the benefit of early preventative
treatment with Hemlibra for babies with severe haemophilia
A
- Phase III HAVEN 7 primary data presented at the ASH annual
meeting 2023 provide additional confidence in the favourable
efficacy and safety profile of subcutaneous Hemlibra given soon
after birth
- At nearly two years median follow-up in the descriptive,
single-arm study, no babies experienced spontaneous bleeds
requiring treatment, and all treated bleeds were a result of
trauma
- Safety results were consistent with previous studies of
Hemlibra, with no new safety signals observed
- The HAVEN 7 study was developed in collaboration with the
haemophilia A community to generate additional evidence for the
prophylactic treatment of infants with haemophilia A
More information: Media Release, 9 December 2023 |
Kadcyla
Breast cancer
|
Kadcyla is the first targeted therapy to show significant
overall survival benefit in people with HER2-positive early-stage
breast cancer with residual invasive disease after neoadjuvant
treatment
- Phase III KATHERINE results reinforce Kadcyla as the standard
of care for this population, with more than 82,000 people treated
to date
- Long-term data also showed continued benefit in invasive
disease-free survival for adjuvant Kadcyla compared to Herceptin in
this study
- These data were presented orally at the 2023 San Antonio Breast
Cancer Symposium (SABCS) and included in the official press
programme
More information: Media Release, 8 December 2023 |
Inavolisib
Breast cancer
|
Inavolisib combination reduces the risk of disease
progression by 57% in people with advanced hormone
receptor-positive, HER2-negative breast cancer with a PIK3CA
mutation
- Inavolisib, an investigational oral therapy, in combination
with palbociclib and fulvestrant more than doubled progression-free
survival compared to palbociclib and fulvestrant alone
- The inavolisib combination has the potential to address
resistance to treatment and poor prognosis associated with PIK3CA
mutations
- These new data were presented orally at the 2023 SABCS and
shared with health authorities
More information: Media Release, 8 December 2023 |
Carmot:
CT-388 and CT-996
Obesity
CT-868
Diabetes type 1 |
Roche enters into a definitive merger agreement to acquire
Carmot Therapeutics, whose portfolio includes three clinical-stage
assets with best-in-class potential in obesity and
diabetes
- Carmot Therapeutics’s research and development portfolio of
clinical-stage incretins has great potential to treat obesity,
diabetes and potentially other diseases both as stand-alone
medicines and in combination with Roche’s in-house assets
- Lead asset CT-388 is a phase II-ready dual GLP-1/GIP receptor
agonist with best-in-class potential for the treatment of obesity
and its comorbidities
- Under the terms of the agreement, Roche will pay a purchase
price of USD 2.7 billion upfront and additional milestone
payments of up to USD 400 million
More information: Media Release, 4 December 2023 |
Elevidys
Duchenne muscular dystrophy
|
EMBARK trial in Duchenne muscular dystrophy (DMD) does not
reach primary endpoint but shows positive efficacy outcomes on all
timed functional key endpoints
- Boys aged 4–7 years with DMD who were treated with Elevidys
showed an increase on the North Star Ambulatory Assessment (NSAA),
a measure of motor function, compared to placebo at 52 weeks, but
the primary endpoint was not met
- For all key pre-specified secondary functional endpoints,
including time to rise and 10-metre walk test across age groups,
clinically meaningful and statistically significant treatment
benefits were observed
- No new safety signals were observed, reinforcing the favourable
and manageable safety profile observed with Elevidys to date
More information: Media Release, 30 October 2023 |
Telavant:
RVT-3101
Inflammatory bowel disease |
Roche entered into a definitive agreement to acquire
Telavant including rights to novel TL1A-directed antibody
(RVT-3101) for the treatment of inflammatory bowel disease from
Roivant
- Roche obtained the rights to develop, manufacture and
commercialise RVT-3101 in the US and Japan for the treatment of
inflammatory bowel disease and potentially multiple other
diseases
- RVT-3101 is a phase III-ready antibody with first-in-class and
best-in-disease potential, a novel mode of action and strong phase
IIb data in ulcerative colitis
- Roche obtained an option to enter into a global collaboration
with Pfizer on a next-generation p40/TL1A directed bispecific
antibody, currently in phase I
- Under the terms of the agreement, Roche paid a purchase price
of
USD 7.1 billion upfront and will pay a near-term
milestone payment of USD 150 million
More information: Media Release, 23 October 2023 |
Other Roche Group news |
Sustainability |
Roche and Chugai named among top three most sustainable
healthcare companies in the Dow Jones Sustainability Indices
(DJSI)
- The ranking acknowledges Roche’s commitment to sustainability
as an integral part of its business strategy
- Roche performed particularly well in innovation management,
access to healthcare, greenhouse gas emissions, water management,
resource efficiency and circularity, labour practice indicators and
human rights
- This marks the 15th consecutive year that Roche has maintained
its leading ranking
- Roche ranked third, Chugai Pharmaceuticals, a member of the
Roche Group, ranked second
More information: Media Release, 15 December 2023 |
Pharmaceuticals sales
Sales |
CHF millions |
As % of sales |
% change |
January–December 2023 |
2023 |
2022 |
2023 |
2022 |
At CER |
In CHF |
Pharmaceuticals Division |
44,612 |
45,551 |
100.0 |
100.0 |
6 |
-2 |
United States |
23,606 |
23,322 |
52.9 |
51.2 |
8 |
1 |
Europe |
8,306 |
8,143 |
18.6 |
17.8 |
6 |
2 |
Japan |
3,745 |
4,949 |
8.4 |
10.9 |
-14 |
-24 |
International* |
8,955 |
9,137 |
20.1 |
20.1 |
13 |
-2 |
*Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia
and Indian subcontinent), Latin America, Middle East, Africa,
Canada, others
Top 20 best-selling pharmaceuticals
|
Total |
United States |
Europe |
Japan |
International |
CHF m |
% |
CHF m |
% |
CHF m |
% |
CHF m |
% |
CHF m |
% |
Ocrevus
Multiple sclerosis |
6,381 |
13 |
4,684 |
11 |
1,166 |
12 |
- |
- |
531 |
31 |
Hemlibra
Haemophilia A |
4,147 |
16 |
2,493 |
14 |
845 |
18 |
373 |
12 |
436 |
29 |
Perjeta2
Breast cancer |
3,768 |
1 |
1,336 |
-7** |
776 |
-8 |
215 |
4 |
1,441 |
16 |
Tecentriq
Cancer immunotherapy |
3,766 |
9 |
1,941 |
4 |
845 |
10 |
419 |
8 |
561 |
29 |
Actemra/RoActemra2
RA, COVID-19 |
2,630 |
5 |
1,223 |
9 |
775 |
0 |
311 |
3 |
321 |
4 |
Vabysmo
Eye diseases (nAMD, DME, RVO) |
2,357 |
324 |
1,914 |
293 |
276 |
*** |
98 |
138 |
69 |
*** |
Xolair2
Asthma |
2,176 |
5 |
2,176 |
5 |
- |
- |
- |
- |
- |
- |
Kadcyla2
Breast cancer |
1,966 |
4 |
757 |
-2 |
577 |
-11 |
102 |
-12 |
530 |
43 |
MabThera/Rituxan2
Blood cancer, RA |
1,630 |
-15 |
987 |
-20 |
180 |
-9 |
24 |
-13 |
439 |
-6 |
Herceptin2
Breast and gastric cancer |
1,626 |
-16 |
331 |
-26 |
353 |
-14 |
30 |
-33 |
912 |
-13 |
Avastin2
Various cancer types |
1,573 |
-19 |
484 |
-19 |
98 |
-47 |
318 |
-26 |
673 |
-7 |
Alecensa
Lung cancer |
1,502 |
8 |
467 |
9 |
292 |
4 |
212 |
5 |
531 |
11 |
Evrysdi
Spinal muscular atrophy |
1,419 |
39 |
505 |
14 |
509 |
49 |
93 |
26 |
312 |
80 |
Activase/TNKase
Cardiac diseases |
1,173 |
6 |
1,112 |
6 |
- |
- |
- |
- |
61 |
5 |
Phesgo
Breast cancer |
1,120 |
64 |
423 |
48 |
534 |
52 |
4 |
- |
159 |
189 |
Polivy
Blood cancer |
837 |
108 |
340 |
119 |
173 |
36 |
227 |
129 |
97 |
317 |
Gazyva/Gazyvaro2
Blood cancer |
811 |
19 |
395 |
22 |
229 |
24 |
38 |
-14 |
149 |
18 |
Ronapreve
COVID-19 |
525 |
-65 |
- |
- |
5 |
-95 |
519 |
-60 |
1 |
-99 |
Lucentis
Eye diseases |
460 |
-52 |
460 |
-52 |
- |
- |
- |
- |
- |
- |
Pulmozyme
Cystic fibrosis |
452 |
-10 |
303 |
-13 |
76 |
-18 |
1 |
8 |
72 |
9 |
** Perjeta sales decline in the US mainly resulted from an
adjustment related to government programmes. Excluding this
adjustment, Perjeta sales in the US showed a growth of 1%.
*** Over 500%
DME: diabetic macular oedema / nAMD: neovascular or ‘wet’
age-related macular degeneration / RVO: retinal vein occlusion /
RA: rheumatoid arthritis
Diagnostics: key milestones in the fourth quarter of
2023
Product |
Milestone |
Elecsys HBeAg quant
Hepatitis B
|
Roche expands hepatitis diagnostics portfolio to help
clinicians diagnose and monitor patients with acute or chronic
hepatitis B infection
- Elecsys HBeAg quant is an immunoassay that can be used as an
early marker of acute hepatitis B infection, as well as an
indicator of chronic active hepatitis in combination with other
laboratory results and clinical information
- The single test will inform clinicians if treatment is required
and regimens are working together with other diagnostic assays
- Almost 300 million people globally have chronic hepatitis B,
causing a significant burden to health systems as it puts patients
at high risk of death from cirrhosis and liver cancer
More information: Media Release, 27 November 2023 |
Elecsys Anti-HEV IgM and Elecsys Anti-HEV IgG
Hepatitis E
|
Roche launches automated serology hepatitis E virus tests,
including a test to detect acute HEV infections, recommended in the
new WHO 2023 Essential Diagnostics List
- It is estimated that one third of the global population could
be at risk for infection with hepatitis E virus
- The new tests allow clinicians to diagnose acute and chronic
infections amongst patients presenting with or without signs of the
illness as recommended by the European Association for the Study of
the Liver (EASL)
- The tests complete Roche’s panel used for the differential
diagnosis of acute viral hepatitis caused by the hepatitis A, B, C
and E viruses
More information: Media Release, 16 November 2023 |
Elecsys NfL test
Multiple sclerosis
|
FDA grants Breakthrough Device Designation for Elecsys NfL
test, an important aid for those living with multiple
sclerosis
- Elecsys NfL aids in detection of disease activity in adults
with multiple sclerosis, supporting better disease management
decisions
- Elecsys NfL offers a minimally invasive testing option that can
provide rapid answers to patients and caregivers
- Elecsys NfL has the potential to provide patient insights for
other neurological conditions such as Alzheimer’s and Huntington’s
diseases
More information: Media Release, 9 November 2023 |
Other Diagnostics news |
LumiraDx
Point-of-care technology platform |
Roche enters into a definitive agreement to acquire
LumiraDx’s point-of-care technology combining multiple diagnostic
modalities on a single platform
- The transformative point-of-care solution will complement
Roche’s centralised diagnostics portfolio across clinical
chemistry, immunochemistry, coagulation and molecular diagnostics,
and across multiple disease areas
- LumiraDx’s technology integrates multiple point-of-care tests
on a simple-to-use single instrument and brings more affordable and
accessible testing to patients worldwide
- Under the terms of the agreement, Roche will pay a purchase
price of
USD 295 million and an additional payment of up to USD 55
million
More information: Media Release, 29 December 2023 |
Diagnostics sales
Sales |
CHF millions |
As % of sales |
% change |
January–December 2023 |
2023 |
2022 |
2023 |
2022 |
At CER |
In CHF |
Diagnostics Division |
14,104 |
17,730 |
100.0 |
100.0 |
-13 |
-20 |
Customer Areas3 |
|
|
|
|
|
|
Core Lab |
7,750 |
7,775 |
55.0 |
43.9 |
9 |
0 |
Molecular Lab |
2,220 |
3,450 |
15.7 |
19.5 |
-30 |
-36 |
Pathology Lab |
1,388 |
1,318 |
9.8 |
7.4 |
14 |
5 |
Point of Care |
1,379 |
3,589 |
9.8 |
20.2 |
-58 |
-62 |
Diabetes Care |
1,367 |
1,598 |
9.7 |
9.0 |
-4 |
-14 |
Regions |
|
|
|
|
|
|
Europe, Middle East, Africa |
4,768 |
5,888 |
33.8 |
33.2 |
-13 |
-19 |
North America |
3,826 |
5,141 |
27.1 |
29.0 |
-21 |
-26 |
Asia–Pacific |
4,496 |
5,639 |
31.9 |
31.8 |
-11 |
-20 |
Latin America |
1,014 |
1,062 |
7.2 |
6.0 |
14 |
-5 |
More information on Roche performance in 2023:
- Full-Year 2023 Finance Report
- Full-Year 2023 Annual Report
- Full-Year 2023 Presentation
- Appendix with Tables
About Roche
Founded in 1896 in Basel, Switzerland, as one of the first
industrial manufacturers of branded medicines, Roche has grown into
the world’s largest biotechnology company and the global leader in
in-vitro diagnostics. The company pursues scientific excellence to
discover and develop medicines and diagnostics for improving and
saving the lives of people around the world. We are a pioneer in
personalised healthcare and want to further transform how
healthcare is delivered to have an even greater impact. To provide
the best care for each person we partner with many stakeholders and
combine our strengths in Diagnostics and Pharma with data insights
from the clinical practice.
In recognising our endeavour to pursue a long-term perspective
in all we do, Roche has been named one of the most sustainable
companies in the pharmaceuticals industry by the Dow Jones
Sustainability Indices for the fifteenth consecutive year. This
distinction also reflects our efforts to improve access to
healthcare together with local partners in every country we
work.
Genentech, in the United States, is a wholly owned member of the
Roche Group. Roche is the majority shareholder in Chugai
Pharmaceutical, Japan.
For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected
by law.
References
[1] Unless otherwise stated, all growth rates and comparisons to
the previous year in this document are at constant exchange rates
(CER: average rates 2022) and all total figures quoted are reported
in CHF.
[2] Products launched before 2015.
[3] Core Lab: diagnostics solutions in the areas of immunoassays,
clinical chemistry and CustomBiotech.
Point of Care: diagnostics solutions in emergency rooms, medical
practices or directly with patients.
Molecular Lab: diagnostics solutions for pathogen detection and
monitoring, donor screening, sexual health and genomics.
Diabetes Care: integrated personalised diabetes management.
Pathology Lab: diagnostics solutions for tissue biopsies and
companion diagnostics.
Cautionary statement regarding forward-looking
statements
This document contains certain forward-looking statements. These
forward-looking statements may be identified by words such as
‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’,
‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or
by discussion of, among other things, strategy, goals, plans or
intentions. Various factors may cause actual results to differ
materially in the future from those reflected in forward-looking
statements contained in this document, such as: (1) pricing and
product initiatives of competitors; (2) legislative and regulatory
developments and economic conditions; (3) delay or inability in
obtaining regulatory approvals or bringing products to market; (4)
fluctuations in currency exchange rates and general financial
market conditions; (5) uncertainties in the discovery, development
or marketing of new products or new uses of existing products,
including without limitation negative results of clinical trials or
research projects, unexpected side effects of pipeline or marketed
products; (6) increased government pricing pressures; (7)
interruptions in production; (8) loss of or inability to obtain
adequate protection for intellectual property rights; (9)
litigation; (10) loss of key executives or other employees; and
(11) adverse publicity and news coverage. The statement regarding
earnings per share growth is not a profit forecast and should not
be interpreted to mean that Roche’s earnings or earnings per share
for this or any subsequent period will necessarily match or exceed
the historical published earnings or earnings per share of
Roche.
Roche Global Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com
Hans Trees, PhD
Phone: +41 79 407 72 58
|
Nathalie
Altermatt
Phone: +41 79 771 05 25
|
Simon
Goldsborough
Phone: +44 797 32 72 915 |
Karsten
Kleine
Phone: +41 79 461 86 83
|
Nina
Mählitz
Phone: +41 79 327 54 74 |
Kirti
Pandey
Phone: +49 172 6367262
|
Dr.
Rebekka Schnell
Phone: +41 79 205 27 03 |
Sileia
Urech
Phone: +41 79 935 81 48 |
- 01022024_MR_Roche FY 2023_en
- Communications appendix tables_FY 2023_Sales & Results
Roche (LSE:0QQ6)
Historical Stock Chart
From May 2024 to Jun 2024
Roche (LSE:0QQ6)
Historical Stock Chart
From Jun 2023 to Jun 2024